Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Articles|June 23, 2016
Kalytera Appoints Robert Langer to Scientific Advisory Board
Author(s)Pharmaceutical Technology Editors
Langer will work with the company to develop its portfolio of cannabidiol candidates for bone health.
Advertisement
Kalytera Therapeutics announced on June 23, 2016 that it has appointed Robert S. Langer to the company’s Scientific advisory board. Kalytera is a California-based pharmaceutical company working to develop a portfolio of non-psychoactive cannabinoid and endocannabinoid medicines.
Langer is a David H. Koch Institute Professor at the Massachusetts Institute of Technology who has received more than 220 awards for his contributions to the drug delivery and tissue engineering fields. Langer will work with Kalytera to advance the company’s portfolio of candidates for bone health.
“Transdermal delivery of cannabidiol, and other proprietary cannabinoids, may confer a variety of benefits to patients,” Langer said in a press announcement. “I look forward to working with Kalytera’s leadership to evaluate and optimally advance the company’s portfolio of drug candidates for bone health.”
Kalytera currently has four drug candidates in its pipeline, including treatments for osteoporosis, bone healing, Prader-Willi Syndrome, and obesity. The company also recently entered into a
Source: Kalytera
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement